Oculis Holding AG (OCS) Net Cash Flow Growth (3y) (2025 - 2026)

Oculis Holding AG (OCS) Net Cash Flow Growth (3y) (2025 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (3y) (Qtr)
1 Oculis Holding AG 66,140.12 Bn 66,139.83 Bn - -50.33%
2 Nanobiotix 1,933.82 Bn 1,933.76 Bn - -
3 Akari Therapeutics 1,022.34 Bn 1,022.34 Bn - -
4 BeOne Medicines 472.04 Bn 467.25 Bn 1.35 Bn 38.47%
5 Vertex Pharmaceuticals 122.28 Bn 115.03 Bn 2.59 Bn 33.37%
6 Regeneron Pharmaceuticals 70.07 Bn 61.31 Bn 3.31 Bn -29.82%
7 Belite Bio 62.66 Bn 62.66 Bn - -
8 Argenx Se 56.16 Bn 50.98 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.56 Bn 34.55 Bn 959.66 Mn 32.17%
10 Revolution Medicines 37.43 Bn 37.43 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2026 -50.33%
Dec 31, 2025 127.49%
Sep 30, 2025 -49.35%